StockNews.com Downgrades Cencora (NYSE:COR) to Hold

Cencora (NYSE:COR) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Tuesday.

A number of other research firms have also issued reports on COR. Wells Fargo & Company upped their target price on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. UBS Group boosted their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Evercore ISI boosted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Finally, Barclays boosted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Price Performance

Shares of Cencora stock traded down $2.03 during trading hours on Tuesday, reaching $253.35. 1,707,405 shares of the company’s stock were exchanged, compared to its average volume of 1,505,253. Cencora has a 1 year low of $214.77 and a 1 year high of $262.26. The company has a market capitalization of $49.13 billion, a P/E ratio of 36.04, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49. The business has a fifty day moving average of $242.78 and a two-hundred day moving average of $238.09. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts predict that Cencora will post 15.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares of the company’s stock, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,648 shares of company stock valued at $2,862,342 over the last 90 days. 10.80% of the stock is owned by insiders.

Institutional Trading of Cencora

Several hedge funds have recently made changes to their positions in COR. JFS Wealth Advisors LLC lifted its position in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after purchasing an additional 46 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Cencora during the fourth quarter worth about $29,000. SBI Securities Co. Ltd. acquired a new stake in shares of Cencora during the fourth quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC lifted its position in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after purchasing an additional 69 shares in the last quarter. Finally, Kentucky Trust Co acquired a new stake in shares of Cencora during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.